DK0972032T3 - Peptider til behandling af systemisk lupus erythematosus - Google Patents
Peptider til behandling af systemisk lupus erythematosusInfo
- Publication number
- DK0972032T3 DK0972032T3 DK98907114T DK98907114T DK0972032T3 DK 0972032 T3 DK0972032 T3 DK 0972032T3 DK 98907114 T DK98907114 T DK 98907114T DK 98907114 T DK98907114 T DK 98907114T DK 0972032 T3 DK0972032 T3 DK 0972032T3
- Authority
- DK
- Denmark
- Prior art keywords
- lupus erythematosus
- systemic lupus
- peptides
- treatment
- laminin
- Prior art date
Links
- 201000000596 systemic lupus erythematosus Diseases 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- YIYCUMYWGOOSNU-FMZZOXHWSA-N 2-[[(2s)-1-[(2s,3s)-2-[[(2s,3r)-2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O YIYCUMYWGOOSNU-FMZZOXHWSA-N 0.000 abstract 2
- 102000007547 Laminin Human genes 0.000 abstract 1
- 108010085895 Laminin Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000010352 biotechnological method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12050397A IL120503A0 (en) | 1997-03-20 | 1997-03-20 | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them |
| PCT/IB1998/000415 WO1998042737A2 (en) | 1997-03-20 | 1998-03-20 | Peptides for the treatment of systemic lupus erythematosus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0972032T3 true DK0972032T3 (da) | 2007-04-10 |
Family
ID=11069947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98907114T DK0972032T3 (da) | 1997-03-20 | 1998-03-20 | Peptider til behandling af systemisk lupus erythematosus |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6228363B1 (da) |
| EP (1) | EP0972032B1 (da) |
| JP (1) | JP4459307B2 (da) |
| AT (1) | ATE348885T1 (da) |
| AU (1) | AU734444B2 (da) |
| CA (1) | CA2283792A1 (da) |
| DE (1) | DE69836679T2 (da) |
| DK (1) | DK0972032T3 (da) |
| ES (1) | ES2279567T3 (da) |
| IL (2) | IL120503A0 (da) |
| NZ (1) | NZ337953A (da) |
| PT (1) | PT972032E (da) |
| WO (1) | WO1998042737A2 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6090200A (en) * | 1999-07-15 | 2001-02-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Peptides and their utility in modulation of behavior of cells expressing alpha3beta1 integrins |
| US7129052B1 (en) * | 2000-07-12 | 2006-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins |
| WO2001061349A1 (en) * | 2000-02-18 | 2001-08-23 | The University Of Tennessee Research Corporation | Detection of microbial deposition and immune response at the basement membrane |
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| EP1594434B1 (en) * | 2003-01-14 | 2016-09-07 | Yeda Research and Development Co. | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| KR20050100616A (ko) * | 2003-01-14 | 2005-10-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 전신성 홍반성 낭창의 치료를 위한 펩티드의 비경구 제제 |
| JP2008539169A (ja) | 2005-04-19 | 2008-11-13 | イーライ リリー アンド カンパニー | 疾患における免疫学的介入のための一価および多価合成多糖類抗原 |
| CN101720231A (zh) * | 2007-05-24 | 2010-06-02 | 哈德西特有限公司 | 治疗全身性红斑狼疮的肽和治疗全身性红斑狼疮的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266328A (en) * | 1990-08-27 | 1993-11-30 | Regents Of The University Of Minnesota | Laminin a chain polypeptides from the carboxy terminal globular domain |
| WO1992004914A1 (en) | 1990-09-14 | 1992-04-02 | The Trustees Of The University Of Pennsylvania | Design of bioactive peptides based on immunoglobulin structure |
| US6013628A (en) * | 1994-02-28 | 2000-01-11 | Regents Of The University Of Minnesota | Method for treating conditions of the eye using polypeptides |
| IL108811A (en) * | 1994-03-01 | 1998-06-15 | Hadasit Med Res Service | Immunoassay reagents, kits and methods |
| US5493008A (en) * | 1994-08-15 | 1996-02-20 | The University Of Virginia Patent Foundation | Two non-contiguous regions contribute to nidogen binding to a single EGF-like motif of the laminin γ1 chain |
| EP0765660A3 (en) * | 1995-09-28 | 1998-09-23 | Takeda Chemical Industries, Ltd. | Microcapsules comprising 2-piperazinone-1-acetic acid compounds |
-
1997
- 1997-03-20 IL IL12050397A patent/IL120503A0/xx unknown
-
1998
- 1998-03-20 CA CA002283792A patent/CA2283792A1/en not_active Abandoned
- 1998-03-20 AT AT98907114T patent/ATE348885T1/de not_active IP Right Cessation
- 1998-03-20 DE DE69836679T patent/DE69836679T2/de not_active Expired - Lifetime
- 1998-03-20 WO PCT/IB1998/000415 patent/WO1998042737A2/en not_active Ceased
- 1998-03-20 JP JP54532898A patent/JP4459307B2/ja not_active Expired - Fee Related
- 1998-03-20 ES ES98907114T patent/ES2279567T3/es not_active Expired - Lifetime
- 1998-03-20 DK DK98907114T patent/DK0972032T3/da active
- 1998-03-20 PT PT98907114T patent/PT972032E/pt unknown
- 1998-03-20 NZ NZ337953A patent/NZ337953A/en unknown
- 1998-03-20 AU AU63065/98A patent/AU734444B2/en not_active Ceased
- 1998-03-20 EP EP98907114A patent/EP0972032B1/en not_active Expired - Lifetime
-
1999
- 1999-09-16 IL IL131950A patent/IL131950A/en not_active IP Right Cessation
- 1999-09-20 US US09/399,494 patent/US6228363B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998042737A3 (en) | 1998-11-05 |
| ES2279567T3 (es) | 2007-08-16 |
| WO1998042737A2 (en) | 1998-10-01 |
| EP0972032A2 (en) | 2000-01-19 |
| JP2001524826A (ja) | 2001-12-04 |
| ATE348885T1 (de) | 2007-01-15 |
| NZ337953A (en) | 2002-03-28 |
| EP0972032B1 (en) | 2006-12-20 |
| AU734444B2 (en) | 2001-06-14 |
| AU6306598A (en) | 1998-10-20 |
| US6228363B1 (en) | 2001-05-08 |
| IL120503A0 (en) | 1997-07-13 |
| CA2283792A1 (en) | 1998-10-01 |
| DE69836679T2 (de) | 2007-10-04 |
| DE69836679D1 (de) | 2007-02-01 |
| JP4459307B2 (ja) | 2010-04-28 |
| IL131950A (en) | 2006-07-05 |
| PT972032E (pt) | 2007-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69533855D1 (de) | UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG | |
| DE59705683D1 (de) | IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG | |
| DE69526120D1 (de) | Verwendung von nebivolol als anti-atherogenisches mittel | |
| DE69823459D1 (de) | Herzbehandlungssystem zur Feststellung und Behandlung von Herzversagen | |
| ATE308327T1 (de) | Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs | |
| ATE242005T1 (de) | P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes | |
| DE3850026D1 (de) | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren. | |
| ATE348885T1 (de) | Peptide zur behandlung des systemischen lupus erythematosus | |
| DE69329656D1 (de) | Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen | |
| BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
| EP0783524A4 (en) | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| ES2130629T3 (es) | Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i. | |
| WO2008142694A3 (en) | Peptides and methods for the treatment of systemic lupus erythematosus | |
| ATE390440T1 (de) | Neuroaktive peptide | |
| DK1039931T3 (da) | Multivalente rekombinante antistoffer til at behandle HRV infektioner | |
| TR200100175T2 (tr) | Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler. | |
| NO963347L (no) | Fremgangsmåte for identifisering av individer som lider av en cellulær abnormitet | |
| DE69712182D1 (de) | Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises | |
| DK0820308T3 (da) | Konjugat til behandling af inflammatoriske sygdomme | |
| EP0790059A4 (en) | Means for treating auto-immune diseases and method of treatment | |
| FI973762A0 (fi) | Ny gen | |
| AU2791295A (en) | Method of determining the amount of active substance released from solid or semi-solid preparations administered to humans or animals | |
| IL114460A0 (en) | Peptide p277 analogs and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |